Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
暂无分享,去创建一个
[1] E. Solary,et al. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. , 1999, Advances in experimental medicine and biology.
[2] C. Wandel,et al. Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.
[3] P. McNamara,et al. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[4] Roman Rouzier,et al. Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma , 2005, Cancer.
[5] A. Vezzani,et al. Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development , 2006, Neurobiology of Disease.
[6] C. Fisher,et al. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. , 2000, European journal of cancer.
[7] J. M. Ford,et al. Pharmacology of drugs that alter multidrug resistance in cancer. , 1990, Pharmacological reviews.
[8] W. Löscher,et al. A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats , 2002, Neuroreport.
[9] R. Callaghan,et al. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. , 2004, European journal of cancer.
[10] D. Kerr,et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[12] T. Fojo,et al. Reversal of multidrug resistance: lessons from clinical oncology. , 2002, Novartis Foundation symposium.
[13] M. Volm,et al. Protein expression profiles indicative for drug resistance of non-small cell lung cancer , 2002, British Journal of Cancer.
[14] B. Smith,et al. Response to ‘comparison of “sequential” versus “standard” chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (aml): results of the uk medical research council aml‐r trial’ , 2003, British journal of haematology.
[15] D. Cohen,et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[16] F. Sturtz,et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] G. Gerrard,et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. , 2004, Haematologica.
[18] T. Grogan,et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Goodman,et al. Tamoxifen Paradoxically Decreases Paclitaxel Deposition into Cerebrospinal Fluid of Brain Tumor Patients , 2005, Journal of Neuro-Oncology.
[20] O. Meijer,et al. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. , 2002, The Journal of endocrinology.
[21] J. Robert. MS-209 Schering. , 2004, Current opinion in investigational drugs.
[22] C. Slapak,et al. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy , 2004, Clinical Cancer Research.
[23] J. Lötsch,et al. Increased CNS uptake and enhanced antinociception of morphine‐6‐glucuronide in rats after inhibition of P‐glycoprotein , 2002, Journal of neurochemistry.
[24] F. Dromer,et al. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[25] P. Sonneveld,et al. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia , 1997, British journal of haematology.
[26] P. McNamara,et al. GF120918, a P-Glycoprotein Modulator, Increases the Concentration of Unbound Amprenavir in the Central Nervous System in Rats , 2002, Antimicrobial Agents and Chemotherapy.
[27] M. Caligiuri,et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. , 2002, Blood.
[28] E. Solary,et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. , 2003, Blood.
[29] R. Advani,et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G R Wilkinson,et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[31] R. Advani,et al. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] F. Balis,et al. Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates , 2000, Cancer Chemotherapy and Pharmacology.
[33] P. Choyke,et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Doroshow,et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.
[35] P. Charlton,et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. , 2001, Cancer research.
[36] H. Altermatt,et al. Multiple drug resistance parameter expression in ovarian cancer. , 1998, Gynecologic oncology.
[37] D. Ross,et al. Novel mechanisms of drug resistance in leukemia , 2000, Leukemia.
[38] E. Mini,et al. Pharmacological strategies for overcoming multidrug resistance. , 2006, Current drug targets.
[39] Willem Boogerd,et al. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] R. Kim,et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. , 1999, Cancer research.
[41] E. Bruera,et al. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. , 1998, British Journal of Cancer.
[42] P J Lucassen,et al. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. , 2001, Endocrinology.
[43] H. McLeod,et al. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar , 2005, British Journal of Cancer.
[44] G. Ehninger,et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia , 2005, British journal of haematology.
[45] L. Hudson,et al. Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats , 1998, Journal of Neuro-Oncology.
[46] J. Schellens,et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093) , 2004, Cancer Chemotherapy and Pharmacology.
[47] Wolfgang Löscher,et al. The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy , 2006, Neurobiology of Disease.
[48] R. Milroy,et al. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. , 1993, British Journal of Cancer.
[49] J. Beijnen,et al. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice , 2004, Cancer Chemotherapy and Pharmacology.
[50] S. Dei,et al. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). , 2006, Current drug targets.
[51] P. Sonneveld,et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. , 2005, Blood.
[52] R. Fanin,et al. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. , 2002, Haematologica.
[53] A. Delmer,et al. Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment , 1997, Annals of Hematology.
[54] T. Fojo,et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] T. Litman,et al. Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833 , 1999 .
[56] J. Beijnen,et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.
[57] E. Aronica,et al. Inhibition of the Multidrug Transporter P‐Glycoprotein Improves Seizure Control in Phenytoin‐treated Chronic Epileptic Rats , 2006, Epilepsia.
[58] P. Corris,et al. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. , 1993, British Journal of Cancer.
[59] J. Verweij,et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[60] J. Schellens,et al. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice , 2004, Investigational New Drugs.
[61] S. Bates,et al. Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.
[62] A. Rzhetsky,et al. The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.
[63] W. Berger,et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications , 2005, Journal of Cancer Research and Clinical Oncology.
[64] Caillot,et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study , 1998, British journal of haematology.
[65] D. Shin,et al. Study of multidrug resistance (mdr1) gene in non-small-cell lung cancer. , 1992, Anticancer research.
[66] N. Bleehen,et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] A. Oza,et al. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours , 2005, Cancer Chemotherapy and Pharmacology.
[68] C. Higgins,et al. The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein , 1999, British journal of pharmacology.
[69] S. Kohno,et al. The clinical role of MDR1 gene expression in human lung cancer. , 1997, Anticancer research.
[70] S. Steinberg,et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma , 2002, Cancer.
[71] E. Solary,et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. , 1996, Blood.
[72] P Bevan,et al. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[73] G. Giaccone,et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy , 1997, International journal of cancer.
[74] M. Sanz,et al. P-glycoprotein expression and prognostic value in acute myeloid leukemia. , 1998, Haematologica.
[75] A. List,et al. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. , 1996, Leukemia.
[76] P. Wood,et al. P‐glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival , 1994, British journal of haematology.
[77] J. Crowley,et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study , 1995, Cancer.
[78] Wolfgang Löscher,et al. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. , 2002, The Journal of pharmacology and experimental therapeutics.
[79] S. Bates,et al. Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation , 1989, Molecular and cellular biology.
[80] J. Chang,et al. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia , 2001, Leukemia.
[81] G. Szakács,et al. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. , 2006, Physiological reviews.
[82] P. Sonneveld,et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. , 2001, Blood.
[83] W. Löscher,et al. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: evidence from microdialysis experiments in rats , 2002, Neuroscience Letters.
[84] P. Charlton,et al. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. , 1999, Bioorganic & medicinal chemistry letters.
[85] S. Raguz,et al. Drug resistance in cancer , 2005, British Journal of Cancer.
[86] M. Gottesman. Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.
[87] P. Choyke,et al. A Phase I study of infusional vinblastine in combination with the p‐glycoprotein antagonist PSC 833 (valspodar) , 2001, Cancer.
[88] J. Schellens,et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. , 2002, Cancer research.
[89] I. Pastan,et al. Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[90] T. Fojo,et al. Strategies for reversing drug resistance , 2003, Oncogene.
[91] Michael Wiese,et al. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. , 2006, Bioorganic & medicinal chemistry.
[92] E. Thiel,et al. MDR-1 Expression and Deletions of Chromosomes 7 and 5(Q) Separately Indicate Adverse Prognosis in AML , 2001, Leukemia & lymphoma.
[93] D. Piwnica-Worms,et al. Imaging Gene Expression in Cancer: Functional Identification of Multidrug Resistance P-glycoprotein In Vivo , 2000 .
[94] H. Coley,et al. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.
[95] M. Lemaire,et al. Role of P‐Glycoprotein in the Blood‐Brain Transport of Colchicine and Vinblastine , 1996, Journal of neurochemistry.
[96] M. Caligiuri,et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] N. Russell,et al. P-glycoprotein in Acute Myeloid Leukaemia: Therapeutic Implications of its Association With Both a Multidrug-resistant and an Apoptosis-resistant Phenotype , 2002, Leukemia & lymphoma.
[98] R. Kim,et al. Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier , 2006, Journal of Pharmacology and Experimental Therapeutics.
[99] W. Wilson,et al. The role of MDR-1 in refractory lymphoma. , 1997, Leukemia & lymphoma.